Skip to main content

Table 2 Treatment-related toxicity.

From: Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte Oncology Network

Higher grade WHO toxicity N = 29
No. (%)
N = 29
No. (%)
N = 29
No. (%)
  1 2 3
Anemia -- 2 (6.9) --
Thrombocytopenia 1 (3.4) -- --
Neutropenia 2 (6.9) 2 (6.9) --
Asthenia 9 (31.0) 2 (6.9) --
Nausea-vomiting 7 (24.1) 1 (3.4) --
Diarrhea 16 (55.1) 2 (6.9) 1(3.4)
Hand-foot syndrome 4 (13.8) 4 (13.8) 2 (6.9)
Mucositis 4 (13.8) 2 (6.9) 1 (3.4)